Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results
- Record quarterly revenues and net income
- Increase in revenue and net income compared to the same period last year
- Strong cash position
- None.
2023 Q2 highlights:
- Revenue was
$18.6 million 25% compared to the corresponding period of 2022 - Net income was
$5.9 million 44% compared to the corresponding period of 2022 - Cash, cash equivalents and short-term investments of
$51.8 million
"We are pleased to report once again record quarterly revenues and pre-tax net income predominately from sales of QuantaFlo® for peripheral arterial disease testing," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "We are encouraged by our results year to date and are highly focused on developing our business in heart dysfunction."
FINANCIAL RESULTS
For the quarter ended June 30, 2023, compared to the corresponding period of 2022, Semler Scientific reported:
- Revenue of
$18.6 million $3.8 million 25% , compared to$14.8 million - Fixed fee software license revenues were
$9.6 million $1.1 million 13% , compared to$8.5 million - Variable fee software license revenues were
$8.4 million $2.4 million 39% , compared to$6.0 million - Sales of other products were
$0.6 million $0.3 million 128% , compared to$0.3 million - Cost of revenues of
$1.2 million $0.2 million 27% , compared to$1.0 million 7% . - Total operating expenses of
$11.4 million $1.8 million 18% , compared to$9.6 million 61% compared to65% . - Pre-tax net income of
$7.7 million $2.5 million 48% , compared to$5.2 million - Income tax expense of
$1.8 million 23% , compared to$1.1 million 22% . - Net income of
$5.9 million $0.88 $0.75 $1.8 million 44% , compared to$4.1 million $0.60 $0.51
Semler Scientific's two largest customers (including their affiliates) comprised
For the six months ended June 30, 2023, compared to the corresponding period of 2022, Semler Scientific reported:
- Revenues of
$36.8 $8.0 million 28% , compared to$28.8 million - Fixed fee software license revenues were
$18.9 million $2.5 million 15% , compared to$16.4 million - Variable fee software license revenues were
$16.9 million $5.0 million 43% compared to$11.9 million - Sales of other products were
$1.0 million $0.4 million 72% , compared to$0.6 million - Cost of revenues of
$2.5 million $0.5 million 29% , compared to$2.0 million 7% . - Total operating expenses, which includes cost of revenues, of
$23.4 million $3.7 million 19% , compared to$19.7 million 64% , compared to68% . - Pre-tax net income of
$14.3 million $5.2 million 57% , compared to$9.1 million - Income tax expense of
$3.5 million 24% compared to$1.7 million 19% . - Net income of
$10.8 million $1.62 $1.38 $3.4 million 46% , compared to$7.4 million $1.10 $0.92
SECOND QUARTER 2023 MAJOR ACCOMPLISHMENTS
- Highest quarterly revenues since inception.
- Highest quarterly pre-tax net income since inception.
- Record cash, cash equivalents and short-term investments balance.
Notice of Conference Call
Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the second quarter ended June 30, 2023, as well as provide a business update on Semler Scientific's strategies for the near-term future.
Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10179834/f9b1852ee8. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:
Domestic callers: (866) 777–2509
International callers: (412) 317–5413
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at www.semlerscientific.com.
Semler Scientific, Inc. Statements of Income Unaudited (In thousands of | ||||||||||||
For the three months ended June 30, | For the six months ended June 30, | |||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||
Revenues | $ | 18,605 | $ | 14,828 | $ | 36,811 | $ | 28,845 | ||||
Operating expenses: | ||||||||||||
Cost of revenues | 1,219 | 963 | 2,488 | 1,932 | ||||||||
Engineering and product development | 1,762 | 1,074 | 3,392 | 2,200 | ||||||||
Sales and marketing | 4,985 | 4,201 | 10,177 | 8,878 | ||||||||
General and administrative | 3,459 | 3,412 | 7,318 | 6,715 | ||||||||
Total operating expenses | 11,425 | 9,650 | 23,375 | 19,725 | ||||||||
Income from operations | 7,180 | 5,178 | 13,436 | 9,120 | ||||||||
Interest income | 597 | 13 | 1,080 | 14 | ||||||||
Change in fair value of notes held for investment | (111) | — | (217) | — | ||||||||
Other income, net | 486 | 13 | 863 | 14 | ||||||||
Pre-tax net income | 7,666 | 5,191 | 14,299 | 9,134 | ||||||||
Income tax provision | 1,787 | 1,117 | 3,451 | 1,700 | ||||||||
Net income | $ | 5,879 | $ | 4,074 | $ | 10,848 | $ | 7,434 | ||||
Net income per share, basic | $ | 0.88 | $ | 0.60 | $ | 1.62 | $ | 1.10 | ||||
Weighted average number of shares used in computing | 6,707,341 | 6,761,050 | 6,704,306 | 6,769,552 | ||||||||
Net income per share, diluted | $ | 0.75 | $ | 0.51 | $ | 1.38 | $ | 0.92 | ||||
Weighted average number of shares used in computing | 7,867,001 | 8,029,302 | 7,887,584 | 8,071,509 | ||||||||
Semler Scientific, Inc. Balance Sheets Unaudited (In thousands of | ||||||
June 30, | December 31, | |||||
2023 | 2022 | |||||
Assets | ||||||
Current Assets: | ||||||
Cash and cash equivalents | $ | 39,495 | $ | 23,014 | ||
Short-term investments | 12,330 | 20,073 | ||||
Trade accounts receivable, net of reserves of | 6,032 | 3,884 | ||||
Inventory, net | 476 | 469 | ||||
Prepaid expenses and other current assets | 2,418 | 1,468 | ||||
Total current assets | 60,751 | 48,908 | ||||
Assets for lease, net | 2,891 | 2,478 | ||||
Property and equipment, net | 796 | 667 | ||||
Long-term investments | 821 | 821 | ||||
Notes held for investment (includes measured at fair value of | 4,962 | 4,679 | ||||
Other non-current assets | 2,736 | 2,842 | ||||
Long-term deferred tax assets | 2,505 | 2,298 | ||||
Total assets | $ | 75,462 | $ | 62,693 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 509 | $ | 835 | ||
Accrued expenses | 8,243 | 4,748 | ||||
Deferred revenue | 1,188 | 1,160 | ||||
Other short-term liabilities | 143 | 114 | ||||
Total current liabilities | 10,083 | 6,857 | ||||
Long-term liabilities: | ||||||
Other long-term liabilities | 116 | 160 | ||||
Total long-term liabilities | 116 | 160 | ||||
Commitments and contingencies (Note 14) | ||||||
Stockholders' equity: | ||||||
Common stock, | 7 | 7 | ||||
Additional paid-in capital | 15,188 | 16,449 | ||||
Retained earnings | 50,068 | 39,220 | ||||
Total stockholders' equity | 65,263 | 55,676 | ||||
Total liabilities and stockholders' equity | $ | 75,462 | $ | 62,693 | ||
Semler Scientific, Inc. Statements of Cash Flows Unaudited (In thousands of | ||||||
Six months ended June 30, | ||||||
2023 | 2022 | |||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net income | $ | 10,848 | $ | 7,434 | ||
Reconciliation of Net Income to Net Cash Provided by Operating Activities: | ||||||
Depreciation | 279 | 309 | ||||
Deferred tax income | (207) | (160) | ||||
Loss on disposal of assets for lease | 114 | 215 | ||||
Allowance for credit losses | 92 | 38 | ||||
Change in fair value of notes held for investment | 217 | — | ||||
Gain on short-term investments | (237) | — | ||||
Stock-based compensation | 860 | 676 | ||||
Changes in Operating Assets and Liabilities: | ||||||
Trade accounts receivable | (2,240) | (1,962) | ||||
Inventory | (7) | 26 | ||||
Prepaid expenses and other current assets | (950) | 1,276 | ||||
Other non-current assets | 106 | (1,960) | ||||
Accounts payable | (326) | 20 | ||||
Accrued expenses | 3,495 | 1,800 | ||||
Other current and non-current liabilities | 13 | 20 | ||||
Net Cash Provided by Operating Activities | 12,057 | 7,732 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Additions to property and equipment | (260) | (258) | ||||
Purchase of notes held for investment | (500) | (1,179) | ||||
Proceeds from maturities of short-term investments | 57,707 | — | ||||
Purchase of short-term investments | (49,728) | — | ||||
Purchase of assets for lease | (674) | (600) | ||||
Net Cash Provided by (Used in) Investing Activities | 6,545 | (2,037) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Taxes paid related to net settlement of equity awards | (172) | (114) | ||||
Common stock warrants acquired | (1,949) | — | ||||
Treasury stock acquired | — | (2,945) | ||||
Proceeds from exercise of stock options | — | 72 | ||||
Net Cash Used in Financing Activities | (2,121) | (2,987) | ||||
INCREASE IN CASH | 16,481 | 2,708 | ||||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 23,014 | 37,323 | ||||
CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | 39,495 | $ | 40,031 | ||
About Semler Scientific, Inc.:
Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the
Forward-Looking Statements
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "believe," "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding developing business in heart dysfunction and diabetes; continued testing of asymptomatic patients; and the benefits of early identification of at-risk patients; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to license its cardiovascular testing products, including the risk of changes in the reimbursement landscape for its customers including related to the recent CMS rate announcement; whether or not it will be able to successfully expand its product offering, including into heart dysfunction and diabetes; whether or not QuantaFlo® can successfully aid in the diagnosis of heart dysfunction; along with those risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
INVESTOR CONTACT:
Renae Cormier
Chief Financial Officer
ir@semlerscientific.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-scientific-reports-second-quarter-and-first-half-of-2023-financial-results-301898239.html
SOURCE Semler Scientific, Inc.
